RE: RNS-INDV Raises Guidance on 2021 Results30 Jun 2021 10:23
In the FTSE 250, Indivior was the standout performer, up 9.5%, after the drugmaker raised its 2021 guidance to reflect increasing business momentum.
Indivior said it expects higher annual net revenue in the range of USD705 million to USD740 million, up from the previously guided up to USD625 million, reflecting a stronger Sublocade performance. Group net revenue was USD647 million in 2020, which was down 18% from USD785 million in 2019.
Net revenue from Sublocade for 2021 is expected to be in the range of USD210 million to USD230 million, up from USD185 million to USD210 million previously guided, based on stronger demand and a large order from a new criminal justice system customer worth USD7 million.
Sublocade is Indivior's lead treatment for opioid addiction.